T. Rowe Price Associates
ITOS

T. Rowe Price Associates’s iTeos Therapeutics ITOS Stock Holding History

T. Rowe Price Associates’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,969
Closed -$150K – 3082
2025
Q2 		$150K Buy
14,969
+2,579
+21% +$20.8K ﹤0.01% 2806
2025
Q1 		$74K Buy
+12,390
New +$91K ﹤0.01% 2878

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's ITOS Position: Q3 2025 in Review

T. Rowe Price Associates sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 14,969 shares — an estimated $150K sold.

T. Rowe Price Associates first reported a position in ITOS in Q1 2025 and held it in 2 quarters. The position peaked at $150K in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • T. Rowe Price Associates reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 14,969 iTeos Therapeutics shares in Q3 2025, an estimated $150K.
  • T. Rowe Price Associates first reported a position in iTeos Therapeutics in Q1 2025 and held it in 2 quarters.
  • T. Rowe Price Associates's iTeos Therapeutics position peaked at $150K in Q2 2025.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.